Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore.
Trends Pharmacol Sci. 2009 Jun;30(6):313-21. doi: 10.1016/j.tips.2009.03.004. Epub 2009 May 14.
Nuclear factor (NF)-kappaB governs the expression of numerous genes that are important for various cellular responses. Its activation is induced by a wide variety of stimuli including stress, cigarette smoke, viral and bacterial products, cytokines, free radicals, carcinogens and tumor promoters to name a few. Deregulation of the NF-kappaB pathway has been observed in and attributed to the development of a variety of human ailments including cancers, autoimmune disorders, pulmonary, cardiovascular, neurodegenerative and skin diseases. Efforts to develop modulators of NF-kappaB have yielded several candidates, some of which are currently in Phase I/II of clinical trials. In addition, it is now becoming apparent that several of the approved drugs being currently used also work, in part, owing to their ability to influence the NF-kappaB pathway. In this article, we focus on the druggable components of the NF-kappaB signaling system and on the recent development of novel therapeutics that target NF-kappaB in various diseases.
核因子（NF）-κB 调控着许多基因的表达，这些基因对于各种细胞反应都很重要。它的激活是由多种刺激诱导的，包括应激、香烟烟雾、病毒和细菌产物、细胞因子、自由基、致癌物和肿瘤促进剂等。NF-κB 通路的失调已在多种人类疾病的发展中观察到，并归因于其发展，包括癌症、自身免疫性疾病、肺部、心血管、神经退行性和皮肤疾病。开发 NF-κB 调节剂的努力已经产生了一些候选药物，其中一些目前正在进行 I/II 期临床试验。此外，现在越来越明显的是，目前正在使用的一些批准药物也在一定程度上发挥作用，这要归功于它们影响 NF-κB 通路的能力。在本文中，我们重点介绍 NF-κB 信号系统的可成药成分，以及针对各种疾病中 NF-κB 的新型治疗药物的最新进展。
